|
|
 |
|
Viewing report
|
|
|
|
Cancer Therapies - Is the United States Always the Most Expensive Market?
Decision Resources, Inc., Sep 2006, Pages: 57
Introduction
The cost of innovative cancer drugs is an increasingly controversial issue. Strict price controls in many countries limit the prices that manufacturers can charge for medicines, whereas the United States’ lenient drug pricing system allows manufacturers much greater latitude to determine launch prices. However, pharmaceutical companies in all countries will need to adapt to a changing pricing environment for oncology drugs.
Get the Answers You Need to Shape Your Strategy
Concern is growing over the rising costs of cancer therapies, particularly in the United States, which has the highest drug prices overall. Have drug manufactures responded to this growing concern? Is government intervention necessary to regulate prices?
Historically, the European hospital sector allowed free pricing of drugs, even in the most heavily regulated markets. But there is a growing trend to control hospital spending on medicines. What pricing controls are being proposed and how will they affect drug pricing in European markets?
Drugs typically do not reach the Japanese market until several years after their launch in the other major pharmaceutical markets. However, Japan recently initiated measures to accelerate the launch of innovative cancer therapies. How will these measures affect future drug pricing and pricing controls in Japan?
Scope
National pricing trends: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Analysis of prices of six drug classes: platinum drugs, hormonal agents, taxanes,
antimetabolites, monoclonal antibodies, and small-molecule tyrosine kinase inhibitors
Outlook and implications for manufacturers: how these trends impact drug manufactures in each market under study
Products Mentioned:
- Alemtuzumab
- Anastrozole
- Bevacizumab
- Bicalutamide
- Capecitabine
- Carboplatin
- Cetuximab
- Cisplatin
- Docetaxel
- Erlotinib
- Gefi tinib
- Gemcitabine
- Goserelin
- Imatinib
- Leuprolide
- Oxaliplatin
- Paclitaxel
- Paclitaxel (modified)
- Panitumumab
- Rituximab
- Trastuzumab
Customers who bought this item also bought
Special Report: 2009 Chartbook of International Pharmaceutical Prices
China Anti-Cancer Drug Market Report 2009
Oncology Market Forecast to 2015: Brand Spending and Development Opportunities
Lung Cancer Therapeutics - Global Strategic Business Report
Pharmaceutical Pricing and Reimbursement in China
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Top 20 Therapy Cancer Brands - Key Brands Set to Consolidate Advantage as Competition Intensifies
Breast Cancer Therapeutics - Global Strategic Business Report
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Stakeholder Opinions: Ovarian Cancer Growing Importance as Secondary Indication for Targeted Therapies
Top 7 Cancer Indications - Therapeutic & Competitive Insights
Pancreatic Cancer Drugs - Global Strategic Business Report
|
|
|
|
